Add BrightSurf on Google Email

VIB (the Flanders Institute for Biotechnology)


A large step forward in the fight against African sleeping sickness

Researchers at VIB have made a significant breakthrough in combating African sleeping sickness by developing a nanobody that carries an ApoL-1 variant to the surface of the parasite. This treatment has shown promising results in mice, with infected animals surviving after a single treatment and the parasite being removed from their blood.

Innovative technology for production of new pharmaceuticals forms basis of new company

Researchers at VIB and VTT have developed a technology that increases the production of secondary metabolites in plant cells, allowing for more efficient pharmaceutical production. This innovation has led to the establishment of SoluCel Ltd., a company focused on bringing this technology platform to the market.

SourceVIB (the Flanders Institute for Biotechnology)·JournalProceedings of the National Academy of Sciences·DateMar 22, 2006

A step forward in the fight against bacterial infections

Researchers at VIB have discovered the mechanism behind reduced inflammation in mice, which produces just enough interferons to activate the immune system against bacteria. This finding is relevant to the quest for new therapeutics for bacterial infections and may provide a breakthrough in combating these deadly diseases.

SourceVIB (the Flanders Institute for Biotechnology)·JournalProceedings of the National Academy of Sciences·DateFeb 1, 2006

Administering stem cells to patients with myocardial infarction leads to a reduction of the infarct

In a double-blind, placebo-controlled study, administering bone marrow stem cells to patients with acute myocardial infarction resulted in a significant reduction of the infarct size and improved regional left ventricle function. The findings suggest potential benefits for targeted clinical and pre-clinical research.